Tranexamic acid for ACE inhibitor induced angioedema

Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation. Tranexamic acid is used in prophylactic management of hereditary angioedema; however, evidence for TXA in angiotensin converting enzyme (ACE) inhibitor-induced angioedema (ACEI-AE) is limited. We describe a patient who presented to the emergency department with ACEI-AE who was successfully treated with TXA. This case suggests that TXA may be a beneficial treatment modality in the management of ACEI-AE and warrants further investigation. (C) 2020 Elsevier Inc. All rights reserved.

Automated summary

Tranexamic acid (TXA), an antifibrinolytic agent, may be a beneficial treatment modality in the management of ACE inhibitor-induced angioedema (ACEI-AE) based on a case report, but further investigation is warranted to confirm its efficacy.